Published

Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of Affective Disorders
Date: 2026-06-01
Source: Crossref
DOI: 10.1016/j.jad.2026.121423
PubMed: 41707717

Authors

Weintraub Marc J.Jeffrey Jessica K.Ichinose Megan C.Bergman R. Lindsey Shapiro Benjamin Barnett Gregory Artin Hewa Lynn Marc Salimian Anabel Grody Shelby Ramesh Rahul Eales Lauren Grob Charles S.Miklowitz David J.

Watch author

Derived topics and classifications

psilocybin Depression Other

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1176/appi.ajp.20231063 10.1016/s0005-7894(04)80036-4 10.1001/jamapsychiatry.2017.2164 10.1001/jamapsychiatry.2022.2096 10.1089/psymed.2023.0007 10.1016/s2215-0366(16)30065-7 10.1056/nejmoa2032994 10.1016/j.tics.2010.06.007 10.1038/s44159-024-00355-4 10.1002/wps.20346 10.1001/jamapsychiatry.2020.3285 10.1016/j.jad.2024.09.133

Indexed papers citing this DOI

Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial2026-06-01

Related papers

Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)ClinicalTrials.gov · 2026-05-14 Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive DisorderClinicalTrials.gov · 2026-05-04 Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.Psychedelic medicine (New Rochelle, N.Y.) · 2023-12-01 Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-13 Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)ClinicalTrials.gov · 2023-07-06 Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled TrialClinicalTrials.gov · 2026-09-15 TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-09-11 Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's DiseaseClinicalTrials.gov · 2026-09-04